In a nutshell This study evaluated the long-term effectiveness and safety of daratumumab (D; Darzalex) plus bortezomib (V; Velcade) and dexamethasone (d; Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. Some...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.
In a nutshell This study evaluated the effectiveness and safety of brentuximab vedotin (BV; Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the BV plus nivolumab combination...
Read MoreEvaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.
In a nutshell This study evaluated the effectiveness and safety of asciminib (Scemblix) in real-world patients with chronic myeloid leukemia (CML) previously treated with ponatinib (Iclusig). The data showed that asciminib treatment had promising effectiveness in these patients. Some background CML is a type of cancer that starts in blood-forming...
Read MoreEvaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.
In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these...
Read MoreEvaluating the effectiveness and safety of trifluridine-tipiracil plus bevacizumab in patients with resistant metastatic colorectal cancer
In a nutshell This study evaluated the effectiveness and safety of the combination of trifluridine-tipiracil (Lonsurf) and bevacizumab (Avastin) in patients with unresponsive (refractory) metastatic colorectal cancer (mCRC) in a real-world setting. The main finding was that trifluridine–tipiracil plus bevacizumab was safe and effective in...
Read MoreEvaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma.
In a nutshell This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that penpulimab was effective and safe with manageable side effects in these patients. Some background Classical Hodgkin lymphoma (cHL) is a cancer of...
Read MoreEvaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.
In a nutshell This study evaluated the tolerability and effectiveness of combined therapy using venetoclax (Venclexta) and gilteritinib (Xospata) in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with the FLT3 (FMS-related tyrosine kinase 3) mutation. The data showed that a combination of venetoclax and gilteritinib potentially...
Read MoreEvaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.
In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...
Read MoreEvaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.
In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...
Read MoreIbrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.
In a nutshell This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax...
Read MoreEvaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
In a nutshell This study evaluated the long-term effectiveness of fixed-duration treatment with venetoclax (Venclexta) plus rituximab (Rituxan) in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that fixed-duration treatment with venetoclax plus rituximab was effective over the long term in these...
Read MoreEvaluating the effectiveness and safety outcomes of administering radiotherapy at the same time with DCEP salvage chemotherapy in patients with multiple myeloma.
In a nutshell This study investigated the effectiveness and safety outcomes of administering radiotherapy (RT) at the same time as DCEP salvage chemotherapy in patients with unresponsive multiple myeloma (MM). This study concluded that RT administered at the same time with DCEP salvage chemotherapy was effective and well-tolerated by most of the...
Read More